Supplementary protection
LT - Žymėti prostatos specifinio membranos antigeno (PSMA) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti
EN - LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER
SPC
| (11) |
Number of the document |
|
| (68) |
Number of the document |
4095130
|
| (21) |
Application number for Supplementary Protection Certificate |
PA 2024 522 |
| (22) |
Date of filing the application |
2024-07-04 |
| (41) |
Date of publication of the application |
2024-07-25 |
|
Date of publication of SPC |
|
| (24) |
Date of coming into effect of SPC |
|
Applicant
| (71) |
Novartis AG ,
Lichtstrasse 35, 4056 Basel,
CH
|
Grantee
| (73) |
Novartis AG ,
Lichtstrasse 35, 4056 Basel,
CH
|
Attorney or representative
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
Number, date and code of the country of origin of the first authorization to place the medicinal or plant protection product on the market within regional economic community
| (93) |
EU/1/22/1703, 2022-12-09
|
Name of the product protected by the basic patent
| (95) |
Lutecio (177Lu) vipivotido tetraksetanas |
Legal status
|
SPC application published
|
|
